Leal Health Study Reveals Prostate Cancer Patients More Actively Engaged in Seeking Clinical Trials Significantly Earlier in Their Journey Compared to Other Solid Tumor Patients
NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Leal Health ("Leal'' or "the Company''), formerly known as Trialjectory, a patient-first, AI-powered treatment platform revolutionizing patient access to cancer care, announced today that it presented a poster at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, which showed that prostate cancer patients' clinical trial search patterns differ dramatically from those with other solid tumors. Nearly half of prostate cancer patients sought clinical trial options as newly-diagnosed patients compared to about one-third of the patient population for other solid tumors.
- Nearly half of prostate cancer patients sought clinical trial options as newly-diagnosed patients compared to about one-third of the patient population for other solid tumors.
- The poster, titled, "Prostate cancer patients consider clinical trial options significantly earlier in their journey compared to other solid tumor patients," analyzed 35,670 patient profiles on Leal's digital platform, comparing disease characteristics between those with prostate cancer and other cancer types, such as bladder, colon, lung and breast cancer.
- Leal's study also explored the impact of digital clinical trial search patterns among prostate cancer patients.
- Concluded Dr. Gaziel, "Despite the major interest coming from patients, there are fewer prostate cancer trial options available to newly diagnosed patients.